HERO (Hemophilia Experiences, Results and Opportunities) is an international, multidisciplinary initiative led by the HERO International Advisory Board and supported by Novo Nordisk.

At the heart of the HERO initiative is the HERO study, the largest ever, multinational, multi-method study of 1386 people in 11 countries.

HERO aims to improve outcomes in hemophilia by calling for and enabling enhanced psychosocial support based on increased understanding and awareness of the issues.